Information Provided By: 
Fly News Breaks for January 13, 2020
SNY, REGN
Jan 13, 2020 | 11:11 EDT
Piper Sandler analyst Christopher Raymond noted that Regeneron pre-announced Q4 U.S. Eylea sales of $1.22B, which beat the consensus forecast of $1.202B. Regeneron has generally guided on expenses in early January but "it's not entirely surprising" that no FY20 cost guidance or pre-releases for Dupixent or other Sanofi-partnered programs was issued today given the recently-announced changes to the Sanofi partnership, Raymond said. The analyst, who added that pipeline timelines appear to be on track, keeps an Overweight rating on Regeneron shares.
News For REGN;SNY From the Last 2 Days
